Planview Recognized as a Leader for Third Consecutive Year in 2022 Gartner® Magic Quadrant™ for Enterprise Agile Planning Tools
27.4.2022 18:35:00 EEST | Business Wire | Press release
Planview ®, the global leader in Portfolio Management and Work Management, today announced it has been named a Leader in the 2022 Gartner Magic Quadrant for Enterprise Agile Planning Tools1 for the third year in a row, based on its Ability to Execute and Completeness of Vision. This news comes on the heels of Planview’s recent announcement that it is a Leader in the 2022 Gartner Magic Quadrant for Strategic Portfolio Management 2.
Download a complimentary copy of the 2022 Gartner Magic Quadrant for Enterprise Agile Planning Tools report.
“The past few years have been a whirlwind, as organizations have had to transform their businesses and pivot their strategies in light of significant macro shifts in the market,” said Louise Allen, Planview Chief Product Officer. “Planview’s Enterprise Agile Planning capabilities have successfully helped organizations evolve and accelerate Agile transformation by providing a foundation for change. Whether an organization is at the beginning of their transformation or further along, Planview empowers organizations to connect strategy to delivery.”
According to Gartner, “Enterprise Agile is a steadily growing mainstream practice. Organizations adopting enterprise Agile development are challenged to coordinate the work of multiple Agile teams and adapt their governance and leadership processes to support Agile methodologies. EAP tools help with this by providing increased visibility into the delivery of work.”
Planview was also recognized in the Gartner® companion piece to the Magic Quadrant, the Critical Capabilities for Enterprise Agile Planning Tools report3. This report evaluates vendor solutions on a set of product features and capabilities and discusses how those apply to important use cases. Planview received the highest score in two Use Cases: the Digital Product Portfolio and Hybrid Project, Program and Product Portfolio Use Cases. Planview also tied for the highest score in the Scaled Agile Framework (SAFe) Use Case.
To learn more about Planview’s Enterprise Agile Planning solution visit: www.planview.com/enterprise-agile-planning.
1 Gartner, Magic Quadrant for Enterprise Agile Planning Tools by Bill Blosen, Mike West, Keith Mann, Deacon D.K. Wan, Akis Sklavounakis, Hassan Ennaciri, and Sarah Davies, April 25, 2022.
2 Gartner, Magic Quadrant for Strategic Portfolio Management by Anthony Henderson and Daniel Stang, April 18, 2022.
3 Gartner, Critical Capabilities for Enterprise Agile Planning Tools by Mike West, Keith Mann, Deacon D.K. Wan, Bill Blosen, Hassan Ennaciri, Wan Fui Chan, and Sarah Davies, April 25, 2022.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER, Magic Quadrant and Critical Capabilities are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005761/en/
Contact information
Leslie Marcotte, lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 13:00:00 EET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 12:40:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss on intangible assets to income from operations was
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 12:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding to 30 by the end of 2026 Introduction of NIQ’s exclusive EQ2 metric, multiplying units by number in pack to reflect true consumption “The pace of
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 09:47:00 EET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom